Charles River Laboratories International, Inc. and Curigin, a Korean biotechnology company developing innovative oncolytic ribonucleic acid interference (RNAi) gene therapies, announced a collaboration for adenoviral vector production. The gene therapy developer will leverage Charles River's market-leading expertise in contract development and manufacturing organization (CDMO) solutions to support its preclinical and clinical trials. Curigin develops anticancer gene therapy products that utilize innovative genetically engineered viruses and novel RNAi technology to quickly and accurately block key disease-specific genetic signal pathways, effectively switching off genes responsible for tumour growth. These gene therapies serve an unmet clinical need and can be offered to patients who have not been treated with conventional cancer drugs. Curigin
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!